INTRODUCTION
The endothelium forms the luminal surface of the vascular system and plays diverse physiological roles in blood-tissue homeostasis and in tissue remodelling during repair and differentiation. Correspondingly, morphological and functional changes of the endothelium are affected in such pathological conditions as atherosclerosis, hypersensitivity, inflammation and tumour metastasis (for reviews, see Levine et al., 1983; Wight et al., 1988) .
The endothelium exists as a monolayer of highly flattened cells which are in intimate contact with the surrounding matrix and are thought to interact with matrix molecules in a dynamic fashion. One characteristic group of molecules, the proteoglycans, appear to be present in the matrix as well as on the endothelial cell surface. Thus electron microscopic studies (Simionescu et al., 1981) have demonstrated that a significant number of anionic sites present on the surface of capillary endothelium could be removed by perfusion with chondroitinase ABC (EC 4.2.2.4 ; chondroitin ABC lyase) and/or heparitinase (EC 4.2.2.8; heparan sulphate lyase). Biochemical analysis (Oohira et al., 1983; Hiss et al., 1987) has shown that bovine aortic endothelial cells in culture synthesize and secrete heparan sulphate proteoglycans of different molecular sizes plus a small (Mr 130000) chondroitin sulphate proteoglycan. We do not know, however, how many subspecies or subpopulations are involved in the major endothelial proteoglycans and whether they have specialized functions. Previously, Marcum et al. (1986) reported that endothelial heparan sulphate proteoglycans contain a small subpopulation capable of binding to anti-thrombin, which may be responsible for the non-thrombogenic properties of the vascular endothelium. , on the other hand, demonstrated that the synthesis of chondroitin sulphate/dermatan sulphate proteoglycans is greatly increased when confluent endothelial cells are subjected to multiscratch wounding to induce migration, suggesting that a modification of the proteoglycan composition may be important in the proliferation and migration of endothelial cells after injury in vivo. Together, these results are suggestive of a diversity of endothelial proteoglycan subspecies that may be related to the diverse physiological roles of the endothelium.
Our interest in vascular endothelial cells and the surrounding matrix stems in part from our earlier observations concerning the strikingly increased synthesis of hyaluronate by mouse mammary carcinoma cell variants that had been selected for their increased efficiency in producing pulmonary metastasis after intravenous injection (Kimata et al., 1983) . Since (Kato et al., 1988) were gifts from Dr. M. Kato, Institute for Molecular Science of Medicine, Aichi Medical University, Japan.
The fraction containing hyaluronate/proteoglycan/ link protein (HA/PG/LP) aggregates ('aAl fraction') was prepared from Swarm rat chondrosarcoma as described by Faltz et al. (1979) . The preparation was then subjected to associative Cs2SO4 gradient zonal rate sedimentation in the presence of hyaluronate decasaccharide (10 mol of hexuronate/mol of hyaluronate in aAl fraction) to release link-protein-free proteoglycan molecules from hyaluronate chains (Kimata et al., 1982 (Folkman et al., 1979) . In addition, on a per protein basis, angiotensin-converting enzyme activity was 100 times higher in END-D cell homogenates than in baby hamster kidney (BHK) cell homogenates, a characteristic known to be specific for endothelial cells (Hayes et al., 1978) . Details of the procedures for establishment of END-D cells are described elsewhere (Takeuchi et al., 1985) and can be obtained on application from the authors.
For metabolic labelling, 1 x 107 endothelial cells were plated in 100 mm-diam. plastic tissue culture dishes (Falcon) and cultured in 10 ml of Eagle's minimal essential medium, containing 10 % (v/v) Glycosaminoglycan samples were prepared from the proteoglycan samples by alkaline fl-elimination as described previously (Kimata et al., 1983) . The samples were chromatographed on a Sepharose CL-6B column (0.8 cm x 50 cm) equilibrated and eluted with the same buffer. The Mr of the radioactive peak was estimated from its Ka, using the standard glycomaninoglycans (chondroitin 4-sulphate, Mr 40000; chondroitin 6-sulphate, Mr 12000).
Analysis by SDS/polyacrylamide-gel electrophoresis
Digestion of proteoglycan samples with chondroitinase AC-II, chondroitinase ABC and/or heparitinase and subsequent analysis by SDS/polyacrylamide-gel electrophoresis in 5-15 % (w/v) polyacrylamide running gel/3.75 00 (w/v) polyacrylamide stacking gel was carried out as described previously (Oike et al., 1980; Kato et al., 1987 
Hyaluronate-binding experiments
The hyaluronate-binding activity of proteoglycans was analysed by the hyaluronate-dependent shift from the retarded proteoglycan peak to the excluded one on Sepharose CL-2B column chromatography, taking advantage of the property of the proteoglycan-hyaluronate aggregate of being excluded from the column (Hardingham & Muir, 1972; Hascall & Heinegard, 1974) . In a typical experiment, 330000 c.p.m. (3.4 ,ug as hexuronate) of35SO42--labelled proteoglycan fraction in 4 M-guanidine hydrochloride buffer A was mixed with high-Mr hyaluronate, and then dialysed against 0.1 M-Tris/HCl (pH 9.0)/proteinase inhibitors. In control experiments, hyaluronate was omitted from the reaction mixture. After the dialysis, the mixtures were applied to a Sepharose CL-2B column (0.9 cm x 40 cm) equilibrated with 0.1 M-Tris/HCl (pH 7.0)/proteinase inhibitors. When the effects of hyaluronate decasaccharide or hyaluronate lyase were examined, the dialysed fractions containing proteoglycans bound to hyaluronate were treated with 5 units of hyaluronate lyase (37°C, 4 h) or 2.5 mg of the decasaccharide (room temperature, 2 h) before application to the column. Affinity fractionation of hyaluronate-binding proteoglycans Affinity fractionation utilizing HA/PG/LP-aggregate carrier was used for the separation of the proteoglycans from high-Mr non-proteoglycan proteins and from nonhyaluronate-bound proteoglycans. The experiments were carried out essentially as described by Kimata et al. (1986) . Briefly, 35S042--or [35S]methionine-labelled proteoglycan fractions (3.4 ,tg as hexuronate) in 4 Mguanidine hydrochloride/buffer A were dialysed against 0.1 M-Tris/HCl (pH 9.0)/proteinase inhibitors and then mixed with HA/PG/LP-aggregate carrier (25 ,ug as hexuronate). After incubation at 10°C for 4 h, the mixture was subjected to associative zonal rate sedimentation on a linear Cs2SO4 gradient. In some experiments to confirm binding specificity, hyaluronate decasaccharide or hyaluronate lyase was added to the mixture of the dialysed fraction and the HA/PG/LP-aggregate carrier, and incubated as described above before application to Cs2SO4 zonal rate sedimentation. Other methods Enzymic analysis for glycosaminoglycan compositions was performed as described previously (Kimata et al., 1983) . Hexuronate was determined by the procedure of Bitter & Muir (1962) (Fig. 1) . Before enzyme treatment, a majority of the label in the proteoglycan Vol. 265 (0) hyaluronate, and then dialysed to associative conditions. The dialysed samples were applied to a Sepharose CL-2B column as described in the Experimental section. To aliquots of the dialysed samples was added hyaluronate decasaccharide. The mixtures were incubated at room temperature for 2 h and then applied to the column as described in the Experimental section (A). fraction from media was found in a broad band at or near the origin (Fig. la, lane 1 (Fig. la, lanes 1-4) show the presence of several other bands of low radioactivity. The formation of these bands, however, was not dependent upon the digestion with glycosaminoglycan lyases. The proteoglycan fraction from media was thus shown to contain three chondroitin sulphate proteoglycans with different sizes of core molecules (Mr 550000, 470000 and 43000), one dermatan sulphate proteoglycan with a core molecule of Mr 41000 and one heparan sulphate proteoglycan with a core molecule of Mr 250000.
The proteoglycan fraction prepared from cell layers was analysed in a similar way (Fig. lb) . The profiles of intact and enzyme-treated samples were qualitatively identical with those of the medium samples, except that a protein of Mr 410000 appeared in place of the Mr 250000 protein in the chondroitinase-plus-heparitinase digests (Fig. lb, lanes 6, 7 and 8) . Although the heparan sulphate proteoglycans were not studied in detail, it is of note that the subspecies of Mr 410000 core exhibits a strong cross-reactivity with monoclonal antibodies HK-84 and HK-102 prepared against the core protein of EHS-tumour heparan sulphate proteoglycan low density form (Kato et al., 1988) . Demonstration of hyaluronate-binding proteoglycan Confluent cultures of mouse endothelial cells were metabolically labelled with "5SO42-and radiolabelled proteoglycan fractions were prepared from the media and cell layers as described in Scheme 1. Portions were dialysed to associative conditions with or without hyaluronate. The fractions were then subjected to Sepharose CL-2B column chromatography as described in the Experimental section: As Fig. 2 shows, the addition of hyaluronate caused a distinct shift of about 18 % (medium) or 10% (cell layer) of the label from the retarded peak to the excluded one. It was of note that the marked decrease in label in the retarded peak took place around the fraction of Kav 0.38. The results suggest the presence in both medium -and cell layer of a population of proteoglycan molecules which have the capacity to 1990 64 Ohl interact with hyaluronate to form hyaluronate-proteoglycan aggregates. When aliquots of the proteoglycan fractions mixed with hyaluronate were treated with hyaluronate decasaccharide, there was a marked decrease of 900 (medium) or 830 (cell layer) in radioactivity in the excluded fraction, with a concomitant increase in radioactivity in the retarded fractions where the hyaluronate-dependent decrease had taken place (Fig. 2) . Furthermore, treatment with hyaluronate lyase also gave essentially the same effect (results not shown). This behaviour of the labelled proteoglycans can be taken as confirming the presence of proteoglycan-hyaluronate aggregates. However, there is another possibility, i.e. that radioactive proteoglycans bind indirectly to hyaluronate via the contaminating non-proteoglycan protein(s) which were revealed in Fig. 1 . As will be shown (Fig. 4) , the presence of such radioactive molecules was not observed in the aggregates prepared from [35S]methionine-labelled proteoglycan fractions, suggesting that the possibility is unlikely. Characterization of the hyaluronate-binding proteoglycan
The Sepharose CL-2B column-excluded fractions were prepared from the mixtures of hyaluronate with [35S]methionine-or 35SO42--labelled medium and cell layer samples (see Fig. 2 ). After being subjected to digestion with hyaluronate lyase as described above, the fractions were again applied to the same Sepharose CL-2B column. More than 250% ( (aggregating) and non-aggregating proteoglycans respectively.
The rapidly and slowly sedimenting 35SO42--labelled fractions were subjected to Sepharose CL-2B column chromatography as described in the Experimental section. The label derived from the rapidly sedimenting aggregate fraction was found in a broad peak, which had an earlier elution position (Kav 0.38 for samples from both media and cell layers; see Table 1 ) than the peak of the label from the slowly sedimenting fraction (Kav 0.62 and 0.72 for samples from media and cell layers respectively, results not shown). Thus the hyaluronatebinding proteoglycan molecules were larger in average hydrodynamic size than the population of non-aggregating proteoglycan molecules.
When 35SO42--labelled glycosaminoglycan chains were prepared from the aggregating and non-aggregating proteoglycan samples and chromatographed oR-Sepharose CL-6B, the chains were eluted, in each case, as a broad peak of Kav 0.38, with an estimated Mr of 38000 (Table 1) .
Vol. 265 Further characterization of the labelled glycosaminoglycan chains was carried out using chondroitinase and heparitinase as described in the Experimental section. The chains derived from hyaluronate-binding proteoglycans (the samples from both media and cell layers) were almost totally digested with chondroitinase AC-II or chondroitinase ABC, indicating that they consist largely of chondroitin sulphate. In contrast, the glycosaminoglycans from non-aggregating proteoglycans appear to contain at least two distinct species, heparan sulphate and chondroitin sulphate, in 35SO42-_radio-activity ratios of 1:4 (media) and 1: 2 (cell layers). It is also clear that the chondroitin sulphate chains from hyaluronate-binding and non-aggregating proteoglycans differ with respect to the 6-sulphate/4-sulphate ratio; this was 3.8 and 5.3 for the hyaluronate-binding proteoglycans in media and cell layers respectively, compared with 1.1 and 2.2 for the non-aggregating proteoglycans in media and cell layers respectively.
[35S]Methionine-labelled proteoglycan fractions were subjected to interaction with HA/PG/LP-aggregate carrier under associative conditions, and the resultant radioactive aggregates (rapidly sedimenting fraction in Cs2SO4 gradient) were analysed for labelled proteoglycan core molecules. As Fig. 4(a) shows, the hyaluronate-binding proteoglycan fractions from both media and cell layers yielded a single radioactive band of Mr 550000 after digestion with chondroitinase ABC. The hyaluronatebinding proteoglycan thus appears to be a single chondroitin sulphate proteoglycan species with a large core protein. A similar band also appeared in the gels containing the non-aggregating proteoglycan fraction (Fig.  4b, lanes 6 and 8) (Hascall & Sajdera, 1969 possess identical mobilities in the gels. The basis of this heterogeneity remains to be investigated. Comparative studies with bovine pulmonary arterial endothelial cells To see whether the synthesis of hyaluronate-binding large chondroitin sulphate proteoglycan is restricted to the mouse endothelial cell, we performed a series of comparative studies with a well-characterized endothelial cell line A.T.C.C. CCL 209 established from calf pulmonary arterial endothelium.
Approx. 3 0% (media) and 100% (cell layers) of the 35SO42-label was bound to the hyaluronate in HA/PG/LP-aggregate carrier, as judged by the same criteria employed for the examination of mouse endothelial cell proteoglycan (cf. Fig. 3 ).
As summarized in Table 1 , the hyaluronate-binding proteoglycans from calf and mouse endothelial cell culture are very similar in both the mobility of the core molecule on SDS/polyacrylamide gels and the hydrodynamic size of the intact proteoglycan monomer, although there were some differences in the chain length and sulphation position of chondroitin sulphate chains.
DISCUSSION
In the present study, we have utilized mouse and calf aortic endothelial cell cultures to demonstrate the synthesis of hyaluronate-binding proteoglycan as well as to define the structure of this particular proteoglycan subpopulation. The hyaluronate-binding proteoglycan is hydrodynamically large and contains chondroitin sulphate chains of an average Mr of 39000 attached to a core molecule of Mr 550000. It is noteworthy that this proteoglycan is very similar to the hyaluronate-binding chondroitin sulphate proteoglycan (PG-M) synthesized by the chick limb bud (Kimata et al., 1986 ) with respect to the size of the core molecule. Hyaluronate-binding proteoglycans of large size have also been found in tendon, aorta, bone mesenchyme, smooth muscle cell cultures and glial cell cultures (for a review, see Hassell et al., 1986) . At this time, however, little is known about the structural and functional relationship among these proteoglycans.
A fundamental body of knowledge on the proteoglycan-hyaluronate interaction has been obtained by studies of the large chondroitin sulphate proteoglycans in cartilage. In these molecules, there is a hyaluronatebinding site on the protein core (Hascall & Heinegard, 1974) . A link protein is required to stabilize the proteoglycan-hyaluronate aggregates (Oegema et al., 1977) . Evidence indicates that the PG/HA/LP complex exists in intact cartilage (for review, see Hascall & Hascall, 1981) . In a preliminary experiment, the rapidly sedimenting aggregate fractions were prepared in another way; unlabelled HA/PG/LP-aggregate carrier was first added to the`SO 2--labelled proteoglycan fraction in 4 M-guanidine hydrochloride. The Vol. 265 indication that the aggregate is stabilized by the link protein of cartilage origin, since the addition of hyaluronate decasaccharide is known to be unable to dissociate the proteoglycans from the cartilage link-proteinstabilized proteoglycan-hyaluronate aggregate (Kimura et al., 1979 (Kimura et al., , 1980 . The results can be interpreted as reflecting a difference between the cartilage-and endothelium-type proteoglycans in their core protein structures, and hence in their manner of anchoring in the respective extracellular matrix. What appears to be a link protein has been described in bovine aorta (Gardell et al., 1980) , but whether it represents a link protein specific for the endothelial cell-type proteoglycan remains to be studied.
We previously characterized and compared the glycosaminoglycans of FM3A mouse mammary carcinoma cell line with differing capacities to form experimental pulmonary metastasis following intravenous injection (Kimata et al., 1983) . The studies showed a correlation between increased levels of hyaluronate, apparently occurring in the cell coat, and the enhanced abilities of injected FM3A variants to metastasize. Since one critical stage during blood-borne metastatic spread is circulating tumour cell arrest or attachment to the vascular endothelium, it is possible that some endothelial cell surface factors, such as the hyaluronate-binding proteoglycan, are responsible for the attachment of highly metastatic, hyaluronate-coated FM3A cells by virtue of their ability to interact with hyaluronate.
Chondroitin sulphate proteoglycans within the blood vessel wall have been implicated in many fundamental events associated with atherosclerosis (for reviews, see Levine et al., 1983; Wight et al., 1986) . The demonstration of hyaluronate-binding proteoglycan in aortic endothelial cell cultures has raised an additional question concerning whether this particular proteoglycan subspecies is responsible for the development of atherosclerotic lesions.
